Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azithromycin for cystic fibrosis.

K W Southern1, P M Barker

  • 1Institute of Child Health, University of Liverpool, Royal Liverpool Children's Hospital, Eaton Road, Alder Hey, Liverpool L12 2AP, UK. kwsouth@liv.ac.uk

The European Respiratory Journal
|November 2, 2004
PubMed
Summary

Azithromycin offers a small but significant improvement in respiratory function for cystic fibrosis (CF) patients. Close monitoring for side effects and antibiotic resistance is crucial.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a multidisciplinary syllabus to support the education and training of roles in cystic fibrosis care: An ECFS Education initiative.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

ECFS standards of care on CFTR-related disorders: Identification and care of the disorders.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2024
Same author

ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individuals.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2024
Same author

Letter to the editor: Risk of false newborn screening after intra-uterine exposure to ETI.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2022
Same author

Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2022

Area of Science:

  • Pharmacology
  • Pulmonology
  • Infectious Diseases

Background:

  • Azithromycin is being investigated as a novel therapy for cystic fibrosis (CF) lung disease.
  • Beyond its antibacterial properties, azithromycin exhibits potential anti-inflammatory effects.
  • Unique pharmacokinetic properties of azithromycin may influence resistance patterns.

Purpose of the Study:

  • To review the current evidence on azithromycin's efficacy and safety in managing cystic fibrosis.
  • To discuss the optimal dosing and treatment duration for azithromycin in CF patients.
  • To highlight the importance of monitoring azithromycin resistance in CF clinical practice.

Main Methods:

  • Review of three randomized controlled trials (RCTs) evaluating azithromycin in CF.
  • Inclusion of a recent meta-analysis confirming trial findings.
  • Assessment of reported adverse events and respiratory function improvements.

Main Results:

  • Azithromycin demonstrated a small but statistically significant improvement in forced expiratory volume in one second (FEV1) compared to placebo.
  • Mild adverse events such as wheeze, diarrhea, and nausea were more frequent in one trial.
  • No established consensus exists regarding optimal azithromycin dosage or treatment duration for CF.

Conclusions:

  • Azithromycin shows promise as an adjunctive therapy for CF lung disease, improving respiratory function.
  • Careful patient monitoring is essential due to potential adverse events and emerging resistance.
  • Collaboration between clinical teams and microbiology departments is recommended to track resistance patterns.

Related Experiment Videos